Vowst is approved to prevent recurrences of C. difficile in people 18 and older following antibacterial treatment, according to an April 26 news release from the agency. Four capsules are taken once per day for three consecutive days, and they contain live bacteria manufactured from human fecal matter.
It is the latest drug to be approved for recurrent C. difficile. In November, the FDA approved the first fecal transplant therapy, Rebyota, for people with ongoing C. difficile. On April 12, five medical associations published guidelines on fighting C. difficile infections, which included a call to adopt antimicrobial stewardship programs.
